Belsomra (Suvorexant) Manufacturing, Supply & Shortage History

How Merck Manufactures Suvorexant

Merck & Co. developed suvorexant through its Whitehouse Station research division, advancing the compound from discovery through Phase III as the first-in-class DORA to reach market. The FDA approved suvorexant on August 13, 2014, under NDA 204569, for the treatment of insomnia characterized by difficulty with sleep onset and sleep maintenance 1.

The active pharmaceutical ingredient (API) synthesis involves a multi-step process producing a triazole-based small molecule. Merck's manufacturing sites operate under FDA Current Good Manufacturing Practice (cGMP) regulations. The finished dosage forms are film-coated tablets in four strengths: 5 mg, 10 mg, 15 mg, and 20 mg. The 10 mg dose is the recommended starting strength for most adults, with dose adjustment to 5 mg or up to 20 mg based on clinical response 1.

Because suvorexant is classified as a Schedule IV controlled substance under the Controlled Substances Act, manufacturing quotas are regulated by the DEA 2. This scheduling designation adds a layer of production planning that does not apply to non-scheduled sleep aids like melatonin receptor agonists. Merck must annually petition the DEA for manufacturing quota allocations, and any significant increase in production requires advance regulatory coordination.

The Orexin System and How Suvorexant Works

Suvorexant blocks both orexin receptor subtypes, OX1R and OX2R, with near-equal binding affinity. This is a different pharmacological strategy than benzodiazepines or Z-drugs, which enhance GABAergic inhibition. The orexin neuropeptides (orexin-A and orexin-B, also called hypocretin-1 and hypocretin-2) are produced by a small cluster of neurons in the lateral hypothalamus. These peptides promote and stabilize wakefulness 3.

The registration trial by Herring et al. published in The Lancet Neurology (2014) enrolled 3,038 patients with insomnia in two Phase III studies. Suvorexant at doses of 40 mg and 20 mg significantly improved subjective total sleep time (sTST) and subjective time to sleep onset (sTSO) compared to placebo over 3 months. At the 20 mg dose, sTST improved by approximately 20 minutes more than placebo at month one (P<0.001) 3. Dr. Andrew Krystal of Duke University has stated: "The orexin antagonist approach represents a fundamentally different way of treating insomnia. Rather than sedating the brain, you are reducing the wake drive" 3.

A separate polysomnographic study confirmed objective findings: suvorexant 40 mg/20 mg increased wake-after-sleep-onset (WASO) time reductions of 22.9 minutes and 16.3 minutes, respectively, versus placebo at month one 4. The drug's half-life averages 12 hours, which contributes to sustained sleep maintenance effects but also carries a risk of next-morning drowsiness, particularly at higher doses. The FDA specifically lowered the recommended maximum dose from the originally studied 40 mg to 20 mg based on next-day impairment data.

FDA Approval Timeline and Regulatory History

The regulatory path for suvorexant was notable for dose negotiations between Merck and the FDA. The original NDA submission proposed a maximum dose of 40 mg. Here is a compressed timeline.

Merck filed its NDA in August 2013. The FDA's advisory committee reviewed the application in May 2014, voting 11-to-2 that suvorexant's benefits outweighed risks but expressing concern over high-dose residual effects 5. The FDA approved the drug on August 13, 2014, with a maximum labeled dose of 20 mg rather than 40 mg, citing data on impaired next-morning driving performance at the higher dose 1.

Post-marketing, the FDA issued updated safety communications. In 2019, the agency added a boxed warning to all orexin receptor antagonists (including suvorexant) regarding complex sleep behaviors such as sleepwalking, sleep-driving, and performing other activities while not fully awake 2. This warning also applied to the Z-drugs (zolpidem, zaleplon, eszopiclone), but the absolute incidence of complex sleep behaviors reported with suvorexant was lower in post-marketing surveillance data than that observed with zolpidem.

Supply Chain Structure and Distribution

Merck distributes Belsomra through a standard three-tier pharmaceutical supply chain: manufacturer to wholesaler to pharmacy. The three major U.S. wholesalers (McKesson, AmerisourceBergen, Cardinal Health) carry Belsomra. Because it is a Schedule IV substance, distribution records are tracked through the DEA's Automation of Reports and Consolidated Orders System (ARCOS).

One constraint specific to DORAs is the relatively concentrated manufacturing base. Until generic entry in 2023, Merck was the sole source of suvorexant globally. Single-source manufacturing for any drug increases supply fragility. A facility shutdown, raw-material disruption, or quality deviation at any critical node could interrupt the entire national supply.

The drug's stability profile requires storage at 20-25°C (68-77°F) with excursions permitted to 15-30°C. This is standard for oral solid dosage forms and does not impose the cold-chain requirements that complicate biologic distribution. Film-coated tablets in blister packaging also reduce the moisture-sensitivity risks that affect some hygroscopic APIs.

Shortage History: What the FDA Database Shows

Suvorexant has had a comparatively quiet shortage history. The FDA Drug Shortage Database and the American Society of Health-System Pharmacists (ASHP) shortage resource have not recorded prolonged, nationwide shortages of brand-name Belsomra since its 2014 launch 6.

This stands in contrast to older insomnia medications. Zolpidem (Ambien) experienced repeated supply disruptions in the 2010s, driven by high generic competition, low margins, and periodic manufacturing quality issues. Triazolam (Halcion) saw supply constraints tied to low production volumes and limited manufacturer interest. Suvorexant's relative supply stability likely reflects Merck's single-source manufacturing discipline and the branded product's higher unit price, which maintained production incentives.

The 2020-2021 COVID-19 pandemic disrupted pharmaceutical supply chains broadly. API sourcing from India and China was affected across drug classes. No specific Belsomra shortage was reported during this period, though Merck did report supply-chain monitoring adjustments in its 2020 annual report 7. The broader insomnia drug category did see utilization increases during the pandemic. A 2021 analysis in JAMA Network Open found a 14.8% increase in insomnia medication prescriptions in the first pandemic year compared to 2019 baseline 8.

Generic Entry and Its Impact on Supply

Suvorexant's core Merck patent (U.S. Patent No. 8,329,693) expired in April 2023. Teva Pharmaceuticals received FDA approval for generic suvorexant in January 2023, followed by other manufacturers including Aurobindo and Lupin. Generic availability has changed the supply picture in several important ways.

Multiple manufacturers now produce suvorexant, reducing single-source fragility. Generic competition has lowered per-tablet pricing. Brand Belsomra carried a wholesale acquisition cost of approximately $400-$450 for a 30-tablet supply; generic suvorexant is priced significantly lower 9.

The tradeoff is that generic manufacturers typically operate on thinner margins, which historically correlates with higher shortage risk for generic drugs overall. A Government Accountability Office (GAO) report has documented that 74% of drug shortages between 2013 and 2017 involved generic drugs 6. Whether suvorexant follows this pattern will depend on how many generic suppliers remain commercially viable as price competition intensifies.

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline conditionally recommends suvorexant for sleep-onset and sleep-maintenance insomnia in adults, giving clinicians guideline-level support for prescribing regardless of brand or generic formulation 10.

Suvorexant Versus Other DORAs: Manufacturing Context

Suvorexant was the first DORA approved, but the class now includes lemborexant (Dayvigo, Eisai, approved December 2019) and daridorexant (Quviviq, Idorsia/Lundbeck, approved January 2022). Each is manufactured by a different company at different facilities, creating some class-level supply redundancy.

From a clinical equivalence standpoint, the three DORAs differ in half-life and receptor selectivity. Suvorexant has the longest half-life at approximately 12 hours. Lemborexant's half-life is 17-19 hours. Daridorexant was designed with an 8-hour half-life to reduce next-day residual effects 11. The 2022 QUVIVIQ registration trial (N=930) showed daridorexant 50 mg reduced WASO by 22.8 minutes versus placebo at month one (P<0.001) and improved daytime functioning on the IDSIQ scale, a measure the suvorexant and lemborexant trials did not use as a primary endpoint 11.

Dr. Emmanuel Mignot of Stanford University, a pioneer in orexin research, has noted: "Having three DORAs from three manufacturers is good for patients. Supply chain diversity within a drug class provides clinical alternatives during any single-product shortage" 12.

For prescribers, this means that if suvorexant supply is disrupted, therapeutic alternatives within the same mechanism class exist. This was not the case from 2014 to 2019, when suvorexant was the only available DORA.

Prescribing Considerations Tied to Supply

Clinicians should factor supply reliability into prescribing decisions for chronic insomnia, which often requires long-term pharmacotherapy. Abrupt discontinuation of suvorexant does not produce the rebound insomnia commonly associated with benzodiazepine receptor agonists, based on Phase III discontinuation data showing no significant rebound effect in the first week after stopping 3. This pharmacological property reduces the clinical urgency during a temporary supply gap.

Patients currently taking brand Belsomra can be switched to generic suvorexant at equivalent doses (5, 10, 15, or 20 mg) without dose adjustment 1. The FDA's bioequivalence standards require generic products to achieve 80-125% confidence intervals for AUC and Cmax relative to the reference product.

For patients with hepatic impairment, no dose adjustment is needed in mild-to-moderate cases (Child-Pugh A or B), but suvorexant is not recommended in severe hepatic impairment due to increased exposure 1. Concomitant use with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) requires reducing the suvorexant dose to 5 mg, and concomitant use with moderate CYP3A4 inhibitors warrants a maximum dose of 10 mg.

Patients should take suvorexant within 30 minutes of bedtime, with at least 7 hours remaining before planned awakening. The starting dose is 10 mg; if well tolerated but insufficiently effective, the dose can be increased to 20 mg.